Your browser is no longer supported. Please, upgrade your browser.
Settings
CLLS Cellectis S.A. daily Stock Chart
CLLS [NASD]
Cellectis S.A.
Index- P/E- EPS (ttm)-1.88 Insider Own- Shs Outstand42.49M Perf Week30.24%
Market Cap1.19B Forward P/E- EPS next Y-2.34 Insider Trans- Shs Float42.47M Perf Month83.76%
Income-79.80M PEG- EPS next Q-0.78 Inst Own32.10% Short Float2.41% Perf Quarter71.76%
Sales72.20M P/S16.46 EPS this Y-24.60% Inst Trans2.92% Short Ratio5.54 Perf Half Y78.38%
Book/sh6.83 P/B4.28 EPS next Y-31.50% ROA-4.70% Target Price33.60 Perf Year100.27%
Cash/sh- P/C- EPS next 5Y- ROE-7.20% 52W Range7.32 - 29.53 Perf YTD70.56%
Dividend- P/FCF- EPS past 5Y- ROI-34.10% 52W High-1.11% Beta2.43
Dividend %- Quick Ratio6.00 Sales past 5Y-2.80% Gross Margin- 52W Low298.91% ATR1.49
Employees205 Current Ratio6.10 Sales Q/Q-9.80% Oper. Margin-46.60% RSI (14)79.60 Volatility7.04% 6.05%
OptionableYes Debt/Eq0.36 EPS Q/Q-89.20% Profit Margin-31.10% Rel Volume2.15 Prev Close29.20
ShortableYes LT Debt/Eq0.34 Earnings- Payout- Avg Volume184.56K Price29.20
Recom1.70 SMA2036.41% SMA5049.89% SMA20076.21% Volume0 Change0.00%
Aug-19-20Upgrade Citigroup Neutral → Buy $15 → $32
May-12-20Initiated Robert W. Baird Outperform $20
Mar-06-20Downgrade Goldman Neutral → Sell $15 → $11
Oct-30-19Resumed Guggenheim Buy $28
Aug-09-19Initiated BTIG Research Buy $37
May-24-19Resumed Citigroup Neutral $22
Mar-14-19Initiated William Blair Outperform
Dec-19-18Initiated Goldman Neutral
Jul-16-18Initiated Barclays Overweight $50
Mar-16-18Initiated Guggenheim Neutral
Sep-05-17Reiterated Wells Fargo Outperform $33 → $40
Sep-05-17Downgrade SunTrust Buy → Hold
Mar-02-17Initiated Instinet Buy $49
Feb-28-17Initiated Wells Fargo Outperform
Apr-05-16Initiated Ladenburg Thalmann Buy $45
Mar-02-16Initiated Sun Trust Rbsn Humphrey Buy
Jul-20-15Initiated BofA/Merrill Buy $50
Apr-20-15Initiated Piper Jaffray Overweight $42
Apr-20-15Initiated Jefferies Buy $46
Nov-18-20 07:29AM  
Nov-17-20 08:00PM  
Nov-16-20 04:30PM  
Nov-06-20 04:30PM  
02:00PM  
12:15PM  
Nov-05-20 04:35PM  
Nov-04-20 09:18AM  
Oct-21-20 04:30PM  
Oct-16-20 08:26AM  
Oct-13-20 09:45AM  
Oct-07-20 04:30PM  
Sep-07-20 04:30PM  
Sep-02-20 04:56PM  
Aug-05-20 04:30PM  
Jul-29-20 04:30PM  
Jul-21-20 04:30PM  
04:30PM  
Jul-10-20 06:04PM  
Jul-07-20 08:17AM  
Jul-06-20 05:19PM  
04:33PM  
Jul-05-20 10:28PM  
Jun-30-20 11:30AM  
Jun-29-20 04:30PM  
Jun-25-20 04:30PM  
Jun-10-20 04:30PM  
Jun-08-20 09:05AM  
Jun-03-20 11:30AM  
Jun-01-20 07:56AM  
May-18-20 04:30PM  
May-13-20 09:08AM  
May-12-20 04:30PM  
10:02AM  
May-11-20 04:30PM  
May-09-20 02:00PM  
May-08-20 06:00AM  
May-06-20 04:30PM  
Apr-30-20 06:13PM  
Apr-29-20 04:30PM  
Apr-13-20 04:30PM  
Apr-10-20 05:00PM  
Apr-02-20 12:00PM  
Mar-27-20 11:09AM  
Mar-10-20 04:30PM  
Mar-06-20 04:30PM  
Mar-04-20 04:30PM  
04:05PM  
Feb-25-20 04:30PM  
Feb-21-20 12:00PM  
Feb-18-20 04:30PM  
Feb-07-20 05:00PM  
Jan-27-20 11:01PM  
Jan-15-20 04:30PM  
Jan-13-20 04:15PM  
Jan-09-20 04:30PM  
Jan-06-20 04:30PM  
Jan-02-20 09:16AM  
Dec-31-19 08:45AM  
Dec-17-19 11:13AM  
Dec-02-19 04:30PM  
Nov-21-19 07:22AM  
Nov-20-19 04:30PM  
Nov-13-19 04:30PM  
Nov-06-19 04:47PM  
Oct-31-19 04:30PM  
Oct-30-19 01:15AM  
Oct-29-19 04:30PM  
Oct-04-19 01:02PM  
Oct-01-19 04:30PM  
Sep-15-19 04:23AM  
Aug-06-19 04:30PM  
Jul-08-19 04:30PM  
Jun-26-19 04:30PM  
May-07-19 04:32PM  
Apr-17-19 04:30PM  
Apr-03-19 08:19AM  
Apr-02-19 04:30PM  
Mar-11-19 04:10PM  
Mar-07-19 04:30PM  
02:47PM  
Feb-25-19 05:10PM  
Feb-07-19 07:25AM  
Dec-10-18 04:30PM  
Nov-13-18 04:30PM  
Oct-17-18 08:10AM  
Sep-19-18 04:30PM  
Sep-18-18 04:30PM  
Aug-20-18 07:40AM  
Aug-02-18 04:30PM  
Aug-01-18 04:30PM  
Jun-27-18 04:30PM  
Jun-12-18 04:30PM  
Jun-08-18 09:56AM  
Jun-05-18 07:35AM  
Jun-04-18 04:30PM  
May-22-18 07:59PM  
04:30PM  
May-21-18 08:30AM  
May-15-18 05:50PM  
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); ALLO-501 to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; UCART123 for the treatment of acute myeloid leukemia (AML); and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics. The company was founded in 1999 and is headquartered in Paris, France.